ArticleChinese medicine2025
Corynoline enhances sorafenib sensitivity in hepatocellular carcinoma via NOS3-mediated ROS production.
Article in Chinese medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nano-hydrogel-based delivery system for dihydroartemisinin to enhance cuproptosis and synergize with anti-PD-1 therapy in triple-negative breast cancer.Journal of nanobiotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe clinical application of sorafenib (Sora) in advanced hepatocellular carcinoma (HCC) is greatly limited due to its moderate efficacy and acquired resistance. Combination therapy with other agents holds promise to improve therapeutic efficacy. PURPOSE: Our study aimed to screen alkaloids exerting synergistic anticancer effects with low-dose Sora in HCC treatment and underlie its molecular mechanisms.
methodsCCK-8 assay was used to evaluate the inhibition rates of Sora combined with alkaloids. The most likely binding targets were predicted by molecular docking simulations, and further verified through CETSA and DARTS. ROS levels were measured by flow cytometry. IL-18 levels were detected using ELISA. Nude mouse xenograft models were employed to validate the synergistic anticancer effect.
resultsCo-administration of alkaloids, Cory showed prominent synergistic anticancer properties with Sora. Quantitative proteomic and molecular docking analyses suggested that NOS3 is a potential target of Cory. CETSA and DARTS assay revealed that Cory directly bound to NOS3. Cory increased NOS3 protein expression in a time- and concentration-dependent manner. Mechanistically, both in vitro and in vivo models showed that Cory increased the sensitivity of HCC cells to Sora through NOS3-mediated ROS production and IL-18 secretion. NOS3 knockdown could reverse the synergistic antitumor effect of Cory and Sora. The addition of antioxidant NAC reversed the increased ROS and IL-18 levels in Sora/Cory-treated Huh7 and HepG2 cells.
conclusionsThis study first revealed that Cory acted synergistically with Sora to inhibit HCC growth through NOS3-mediated ROS production and IL-18 secretion, suggesting the potential of Cory as a sorafenib sensitizer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.